BioPhase Solutions

The U.S. Orphan Cures Act now extends price-negotiation exemptions to drugs that treat multiple rare conditions, creating a new financial incentive for innovation in one of biotech’s most challenging sectors.

A small policy shift with a big potential impact.

Read on Wall Street Journal: https://www.wsj.com/articles/a-bright-spot-for-biotech-in-trumps-megabill-53111f1d

A Bright Spot for Biotech in Trump’s Megabill Folded into the blockbuster law that passed this month was the Orphan Cures Act, a measure that spares drugs approved for more than one orphan disease from Medicare price negotiation.

U.S. pharma tariffs could reshape global supply chains.

Starting this August, the U.S. will begin phasing in pharmaceutical tariffs aimed at onshoring drug manufacturing. While this could mean better supply security, it also has global players scrambling. What does it mean for biotech pricing and production?

Dive into the policy impact: https://www.investors.com/news/technology/pharmaceutical-tariffs-august-2025-drug-stocks/

Pharma Tariffs Expected In August. But The Stocks Just Yawned. President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month.